The best indicator for Bio-Techne (TECH)
We backtested 20 indicators across daily, weekly and hourly charts on real Bio-Techne (TECH) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
SMA 50/200 Cross
On the daily chart, this is the strongest risk-adjusted edge we found for Bio-Techne (TECH) over ~37.3 years — trailing buy-and-hold by 5.1% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | SMA 50/200 Cross ✓ | Daily | 13.5% | 0.56 | -67.8% | 63.0% | 27 | -5.1% |
| 2 | EMA 20/50 Cross ✓ | Weekly | 13.4% | 0.56 | -67.6% | 57.9% | 19 | -5.1% |
| 3 | Bollinger Mean-Reversion ✓ | Weekly | 7.5% | 0.53 | -32.8% | 82.8% | 29 | -11.0% |
| 4 | ADX / DMI ✓ | Weekly | 10.8% | 0.52 | -66.4% | 56.0% | 50 | -7.6% |
| 5 | Donchian Breakout ✓ | Weekly | 10.7% | 0.52 | -59.8% | 50.0% | 26 | -7.8% |
| 6 | Stochastic ✓ | Daily | 9.9% | 0.5 | -52.7% | 68.1% | 163 | -8.6% |
| 7 | MACD ✓ | Weekly | 10.2% | 0.5 | -71.1% | 52.6% | 76 | -8.2% |
| 8 | EMA 50/200 Cross ✓ | Daily | 10.7% | 0.48 | -70.6% | 40.6% | 32 | -7.8% |
| 9 | Williams %R ✓ | Daily | 9.9% | 0.48 | -61.0% | 72.8% | 228 | -8.6% |
| 10 | EMA 20/50 Cross ✓ | Daily | 9.7% | 0.46 | -75.5% | 33.3% | 87 | -8.9% |
| 11 | RSI Trend (>50) ✓ | Weekly | 9.6% | 0.46 | -76.0% | 39.5% | 114 | -8.8% |
| 12 | Bollinger Breakout ✓ | Weekly | 8.3% | 0.46 | -61.7% | 54.3% | 35 | -10.2% |
| 13 | WaveTrend (8/6/4) ✓ | Daily | 8.1% | 0.42 | -55.8% | 67.9% | 140 | -10.4% |
| 14 | Williams %R ✓ | Weekly | 6.9% | 0.42 | -49.4% | 67.4% | 46 | -11.6% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Bio-Techne (TECH), SMA 50/200 Cross on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.